Validation of measurement scales in ocular graft-versus-host disease.
Validation of measurement scales in ocular graft-versus-host disease.
复制标题
DOI：
10.1016/j.ophtha.2011.08.040
复制
发表时间：
2012-03
期刊：
影响因子：
13.7
通讯作者：
Chronic GVHD Consortium
中科院分区：
文献类型：
--
作者：
Inamoto Y;Chai X;Kurland BF;Cutler C;Flowers ME;Palmer JM;Carpenter PA;Heffernan MJ;Jacobsohn D;Jagasia MH;Pidala J;Khera N;Vogelsang GB;Weisdorf D;Martin PJ;Pavletic SZ;Lee SJ;Chronic GVHD Consortium
目的：验证异基因造血细胞移植后眼部慢性移植物抗宿主病(GVHD)分级标准的有效性。候选量表被美国国立卫生研究院(NIH)慢性GVHD共识会议推荐用于临床试验，或先前已在干眼综合征中得到验证。前瞻性随访研究。在2007年8月至2010年6月期间，这项研究在多中心、前瞻性、观察性队列中招募了387名慢性移植物抗宿主病患者。使用基于锚的方法，我们将临床医生或患者报告的眼睛症状的变化(8分等级)与计算的5个候选等级的变化进行比较：NIH眼睛评分、患者报告的眼睛症状的全球评级、Lee眼子量表、眼表疾病指数和Schirmer测试。对333次随访的变化进行了检查，其中临床医生和患者都报告了前一次访问中涉及眼睛的情况。线性混合模型被用来解释患者内部的相关性。临床医生或患者报告的症状变化的8分量表被用作在随访时衡量症状变化的锚。在一系列评估中，临床医生和患者之间关于改善、稳定或恶化的一致性是公平的(加权kappa=0.34)。尽管评估者之间只有公平的一致性，但除了Schirmer测试之外，所有的量表都与临床医生报告的和患者报告的眼GVHD活动的变化相关。在所有量表中，NIH眼部评分的变化对临床医生或患者报告的症状变化最敏感。我们的结果支持在评估慢性移植物抗宿主病治疗的临床试验中使用NIH眼部评分作为眼部症状变化的敏感指标。
To validate measurement scales for rating ocular chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation. Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes. Prospective follow-up study. Between August 2007 and June 2010, the study enrolled 387 patients with chronic GVHD in a multicenter, prospective, observational cohort. Using anchor-based methods, we compared clinician or patient-reported changes in eye symptoms (8-point scale) with calculated changes in 5 candidate scales: The NIH eye score, patient-reported global rating of eye symptoms, Lee eye subscale, Ocular Surface Disease Index, and Schirmer test. Change was examined for 333 follow-up visits where both clinician and patient reported eye involvement at the previous visit. Linear mixed models were used to account for within-patient correlation. An 8-point scale of clinician or patient-reported symptom change was used as an anchor to measure symptom changes at the follow-up visits. In serial evaluations, agreement regarding improvement, stability, or worsening between the clinician and patient was fair (weighted kappa = 0.34). Despite only fair agreement between evaluators, all scales except the Schirmer test correlated with both clinician-reported and patient-reported changes in ocular GVHD activity. Among all scales, changes in the NIH eye scores showed the greatest sensitivity to symptom change reported by clinicians or patients. Our results support the use of the NIH eye score as a sensitive measure of eye symptom changes in clinical trials assessing treatment of chronic GVHD.
登录
查看更多内容
影响因子：
4.5
作者：
Acquadro, C;Berzon, R;Rothman, M
通讯作者：
Rothman, M
影响因子：
3.5
作者：
Revicki, DA;Osoba, D;Rothman, M
通讯作者：
Rothman, M
影响因子：
20.3
作者：
Flowers, MED;Parker, PM;Martin, PJ
通讯作者：
Martin, PJ
DOI：
10.1053/bbmt.2002.v8.pm12234170
发表时间：
2002-01-01
影响因子：
4.3
作者：
Lee, SJ;Cook, EF;Antin, JH
通讯作者：
Antin, JH
影响因子：
3
作者：
Norman, GR;Sloan, JA;Wyrwich, KW
通讯作者：
Wyrwich, KW